Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Upon introduction, Sarah was "absolutely blown away" by the science, noting she'd never seen that amount of research in the broader weight management category
Prog Neurobiol (2013) 108:2143
In the SURMOUNT-2 study, which involved 938 adults with obesity or overweight and T2D, tirzepatide showed significant weight loss effects of 13.4% and 15.7% for the 10 and 15 mg doses, respectively, with over 80% of participants experiencing at least a 5% weight loss [92]
Healthcare providers start the medication at a low dose and titrate slowly to reach higher doses
The next-generation GLP-1 drugs pipeline is also relevant context
Heres what early studies have shown: Pancreatitis: Reported in about 0.4% Gallbladder problems: Seen in about 1.1% , with no cases in the placebo group Heart rhythm changes: Reported more often with retatrutide ( about 6% vs 3% with placebo ) Liver enzyme increases: Rare (around 1% ), with overall liver health markers staying stable While these serious side effects were uncommon, theyre still important to keep in mind
